Viewing Study NCT01306032

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 9:42 PM
Ignite Modification Date: 2026-02-18 @ 8:47 PM
Study NCT ID: NCT01306032
Status: COMPLETED
Last Update Posted: 2017-04-26
First Post: 2011-02-26
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Phase II ABT-888 With Cyclophosphamide
Sponsor: National Cancer Institute (NCI)
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Ovarian Cancer View
None Primary Peritoneal Cancer View
None Serous Carcinoma Cancer View
None Triple-Negative Breast Cancer View
None Fallopian Tube Cancer View
Keywords:

Keywords

Keyword Brief Keyword Text View
None PARP Inhibitor View
None BRCA Mutations View
None DNA Damage Repair View
None Pharmacodynamics View
None Metronomic Cyclophosphamide View
None Ovarian Cancer View
None Breast Cancer View
None Fallopian Tube Cancer View
None Peritoneal Cancer View